Loading...
Loading...
VBLT| Name | Value |
|---|---|
| Revenues | 481.0K |
| Cost of Revenue | 63.0K |
| Gross Profit | 418.0K |
| Operating Expense | 9,693.0K |
| Operating I/L | -9,275.0K |
| Other Income/Expense | 105.0K |
| Interest Income | 140.0K |
| Pretax | -9,170.0K |
| Income Tax Expense | -105.0K |
| Net Income/Loss | -9,065.0K |
Vascular Biogenics Ltd. is a clinical stage biopharmaceutical company specializing in the development of therapeutics for cancer and immune-inflammatory diseases. The company's primary focus is on its lead product candidate, VB-111, a gene-based biologic currently in Phase III clinical trials for recurrent platinum-resistant ovarian cancer, with additional Phase II trials for recurrent glioblastoma and colorectal cancer. Vascular Biogenics is also developing VB-601 for various inflammatory indications and VB-611 for various solid tumors. The company's revenue is generated through the development and potential commercialization of these innovative therapeutics targeting newly formed blood vessels and monocyte migration.
